Physician profile
James E Haney
NPI 1184782138
$3,524.18
in general payments reported to CMS, 2019-2025
25 companies · $598 in 2025
The $598 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $708 · 2020: $119 · 2021: $151 · 2022: $265 · 2023: $1,037 · 2024: $647 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,280.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $664.99 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Teva Pharmaceuticals USA, INC. | $364.37 | 2019-2022 | |
| Glaxosmithkline, LLC. | $322.67 | 2022-2025 | Arexvy, Trelegy Ellipta |
| Abbvie INC. | $308.08 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $266.92 | 2019-2021 | |
| Amarin Pharma, INC. | $144.64 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $136.06 | 2023 | |
| Boston Scientific Corporation | $130.85 | 2023 | Watchman Access System |
| Lilly USA, LLC | $126.30 | 2024-2025 | Mounjaro, Zepbound |
| Aimmune Therapeutics, INC. | $125.00 | 2025 | Zenpep |
| Sanofi Pasteur INC. | $124.33 | 2019-2023 | |
| Modernatx, INC. | $120.67 | 2023 | Moderna Covid-19 Vaccine |
| Abbott Laboratories | $117.01 | 2023 | Freestyle Libre 2 |
| Alnylam Pharmaceuticals INC. | $110.88 | 2023 | Amvuttra |
| Novo Nordisk INC | $95.40 | 2020-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $81.15 | 2019 | |
| Pfizer INC. | $80.52 | 2019-2024 | |
| Exact Sciences Corporation | $64.63 | 2023-2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $44.71 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $26.70 | 2022 | |
| Cardiovascular Systems INC. | $16.27 | 2020 | |
| Phadia US INC. | $13.56 | 2021 | |
| Dexcom, INC. | $13.42 | 2022 | |
| Shield Therapeutics INC | $12.86 | 2022 | |
| Allergan, INC. | $12.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Haney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.